high-risk cutaneous squamous cell carcinoma | News Search

跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

找到 113,141 条关于 “high-risk cutaneous squamous cell carcinoma”

Mixed Results for Adjuvant Immunotherapy in High-Risk Cutaneous Squamous Cell Carcinoma

Multidisciplinary Coordination and Emerging Biomarkers Transform Care for High-Risk Cutaneous Squamous Cell Carcinoma

Study of Adjuvant Cemiplimab Versus Placebo After Surgery for High-Risk Cutaneous Squamous Cell Carcinoma

Cemiplimab Shows Promise in Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma

Regeneron Announces Phase III Success for Libtayo in Skin Cancer Treatment

Regeneron's Libtayo Shows Significant DFS Improvement in High-Risk CSCC Adjuvant Trial

Libtayo Demonstrates Significant Disease-Free Survival Improvement in High-Risk CSCC

NICE Initiates Appraisals for Two Cancer Immunotherapies: Sasanlimab-BCG Combination and Cemiplimab Adjuvant Treatment

FDA Expands Dermatology Drug Labels in 2025 with Five New Indications Across Multiple Skin Conditions

Regeneron Presents New Libtayo Data at ESMO 2025, Showcasing Patient-Centric Every 6-Week Dosing for High-Risk Skin Cancer

第 1 页，共 2611 页